# TB-500 dosage & reconstitution (5 mg vial)

TB-500 dosage: calculations for a 5 mg vial use the same amounts described in the literature. Adding 1 mL of bacteriostatic water produces 5 mg/mL, so each U-100 unit contains 50 mcg.

- **Vial contents:** 5 mg TB-500
- **Final volume:** 1 mL
- **Concentration:** 5 mg/mL
- **One U-100 unit:** 50 mcg in 0.01 mL

## Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing

### Standard / Gradual Approach (1 mL = ~5 mg/mL)

| Week / phase | Daily dose | Units per injection (mL) |
|---|---|---|
| Weeks 1–2 | 500 mcg | 10 units (0.10 mL) |
| Weeks 3–4 | 600 mcg | 12 units (0.12 mL) |
| Weeks 5–8 | 750 mcg | 15 units (0.15 mL) |
| Weeks 9–12 | 1 mg (1000 mcg) | 20 units (0.20 mL) |

Frequency: Once daily, subcutaneously, at a consistent time.

### Reconstitution Steps

1. Draw 1 mL of bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid shaking to prevent foaming.
3. Gently swirl or roll until fully dissolved (clear solution).
4. Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.

Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

## U-100 Conversion Table

| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 50 injections |
| 5 | 0.05 mL | 250 mcg | 20 injections |
| 10 | 0.10 mL | 500 mcg | 10 injections |
| 20 | 0.20 mL | 1 mg (1000 mcg) | 5 injections |
| 30 | 0.30 mL | 1.5 mg (1500 mcg) | 3 injections |
| 50 | 0.50 mL | 2.5 mg (2500 mcg) | 2 injections |
| 100 | 1.00 mL | 5 mg (5000 mcg) | 1 injection |

## Supplies Needed

**TB-500 vials (5 mg each)**
- Standard / Gradual Approach, 12 weeks: Minimum 13 vials (64.4 mg required).
- Standard / Gradual Approach, 24 weeks: Minimum 30 vials (148.4 mg required).

**U-100 syringes (1 mL)**
- Standard / Gradual Approach, 12 weeks: 84 new syringes for 84 injections.
- Standard / Gradual Approach, 24 weeks: 168 new syringes for 168 injections.

**Bacteriostatic water**
- Standard / Gradual Approach, 12 weeks: 13 mL total (1 mL per vial) → 5 × 3 mL vials.
- Standard / Gradual Approach, 24 weeks: 30 mL total (1 mL per vial) → 10 × 3 mL vials.

**Alcohol swabs**
- Standard / Gradual Approach, 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Standard / Gradual Approach, 24 weeks: 336 minimum; one box of 100 does not cover the calculation.

## Storage Instructions

- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.

## How This Works

TB-500 is the synthetic form of the active fragment (amino acids 1-43) of Thymosin Beta-4 (Tβ4), an endogenous 43-amino-acid peptide (MW: 4963.4 Da) highly conserved evolutionarily. Present in elevated concentrations in platelets, leukocytes, and healing tissues, TB-500 orchestrates multiple regenerative processes. Structure and Molecular Characteristics: Secuencia: Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES Critical active region: peptide 1-4 (Ac-SDKP) with independent anti-inflammatory effects Actin-binding domain: amino acids 5-20 (primary mechanism) Stability: high resistance to serum proteases Hydrophilicity: excellent aqueous solubility without aggregation Mecanismos Moleculares Fundamentales: Actin Sequestration and Regulation: Monomeric G-actin binding: 1:1 ratio (Kd ~0.5 μM) Prevention of premature actin polymerization Dynamic cytoskeleton regulation during cell migration Intracellular concentration: 400-500 μM in thymic cells Signaling Cascades: Vía ILK (Integrin-Linked Kinase): Activación vía integrina → ILK → Akt (supervivencia celular) GSK-3β phosphorylation: apoptosis inhibition Survival gene expression: Bcl-2, Bcl-xL Vía VEGF/Angiogénesis: VEGF-A upregulation:…

## Research FAQ

**Q: TB-500 vs BPC-157 for regenerative research?** A: Complementary mechanisms with different optimal applications:
**P: ¿Protocolo loading vs mantenimiento?** Fase Loading (semanas 1-2): 2.5x standard dose, 3x/week Ejemplo: 10 mg/kg vs 4 mg/kg mantenimiento en ratas
**P: ¿Tiempo óptimo administración post-lesión?** A: Wide therapeutic window, but timing matters:
**P: ¿Vía administración óptima?** A: Depends on the application:
**Q: Synergistic combinations with other agents?** A: Combinations studied with additive/synergistic effects:

## References

1. Sosne G, et al. (2010) “Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo” – Exp Eye Res 90(4):478-486. [PubMed: 20036654]
2. Crockford D, et al. (2011) “Thymosin Beta4: Structure, Function, and Biological Properties Supporting Current and Future Clinical Applications” – Ann NY Acad Sci 1269:133-138. [PubMed: 22823477]
3. Sosne G, et al. (2015) “Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent” – Clin Ophthalmol 9:1277-1285. [PubMed: 26203211]
4. Bock-Marquette I, et al. (2004) “Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair” – Nature 432(7016):466-472. [PubMed: 15565145]
5. Philp D, et al. (2003) “Thymosin beta4 promotes matrix metalloproteinase expression during wound healing” – J Cell Physiol 194(3):355-361. [PubMed: 12548555]
6. Hinkel R, et al. (2008) “Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection” – Circulation 117(17):2232-2240. [PubMed: 18427126]
7. Garbayo E, et al. (2016) “Catheter-based Intramyocardial Injection of FGF1 or NRG1-loaded MPs Improves Cardiac Function in a Preclinical Model of Ischemia-Reperfusion” – Sci Rep 6:25932. [PubMed: 27181748]
8. Young JD, et al. (1999) “Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids” – Nat Med 5(12):1424-1427. [PubMed: 10581087]

---
Source: https://protocolopeptidos.com/en/compuestos/tb-500-5mg · Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.